BACKGROUND: Dysregulation of the insulin-like growth factor (IGF) system, a common consequence of adiposity-induced insulin resistance, may be a key underlying mechanism linking excess body weight with colon cancer. Evidence has been derived from studies of cancer and polyps. Supporting data about aberrant crypt foci (ACF), putative pre-polyp changes, have been generated only from animal studies to date. METHODS: We randomly selected 26 patients with sex-specific elevated waist-hip-ratio (WHR) and 26 with normal values from a series of 150 patients seeking routine colonoscopy at the University of Connecticut Health Center. Cross-sectional analyses were performed of ACF number (<5, > or = 5) in relation to total IGF1, IGF-binding protein-3 (IGFBP3), insulin, body mass index (BMI), WHR and waist circumference (WC). Visualized ACF in the 20 cm of the distal colon were counted using advanced endoscopic imaging. RESULTS:Patients with > or = 5ACF had higher BMI, WHR, and WC compared with patients with >5 ACF (p = 0.04, p = 0.03, and p = 0.01, respectively). IGFBP3 was reduced (p = 0.02) and IGF1:IGFBP3molar ratio was greater (p = 0.03) in patients with > or = 5ACF. We did not observe significant associations between ACF number and insulin or total IGF1. CONCLUSIONS: Our study provides the first report in humans of a possible association of ACF prevalence and IGF1 bioavailability as characterized by IGF1:IGFBP3molar ratio and IGFBP3 level. More research is needed to determine whether this relationship is varied by ACF features (e.g., size, dysplasia, molecular changes), synchronous cancer and polyps, and is modified by colon cancer risk factors.
RCT Entities:
BACKGROUND: Dysregulation of the insulin-like growth factor (IGF) system, a common consequence of adiposity-induced insulin resistance, may be a key underlying mechanism linking excess body weight with colon cancer. Evidence has been derived from studies of cancer and polyps. Supporting data about aberrant crypt foci (ACF), putative pre-polyp changes, have been generated only from animal studies to date. METHODS: We randomly selected 26 patients with sex-specific elevated waist-hip-ratio (WHR) and 26 with normal values from a series of 150 patients seeking routine colonoscopy at the University of Connecticut Health Center. Cross-sectional analyses were performed of ACF number (<5, > or = 5) in relation to total IGF1, IGF-binding protein-3 (IGFBP3), insulin, body mass index (BMI), WHR and waist circumference (WC). Visualized ACF in the 20 cm of the distal colon were counted using advanced endoscopic imaging. RESULTS:Patients with > or = 5 ACF had higher BMI, WHR, and WC compared with patients with >5 ACF (p = 0.04, p = 0.03, and p = 0.01, respectively). IGFBP3 was reduced (p = 0.02) and IGF1:IGFBP3 molar ratio was greater (p = 0.03) in patients with > or = 5 ACF. We did not observe significant associations between ACF number and insulin or total IGF1. CONCLUSIONS: Our study provides the first report in humans of a possible association of ACF prevalence and IGF1 bioavailability as characterized by IGF1:IGFBP3 molar ratio and IGFBP3 level. More research is needed to determine whether this relationship is varied by ACF features (e.g., size, dysplasia, molecular changes), synchronous cancer and polyps, and is modified by colon cancer risk factors.
Authors: Katherine Delellis Henderson; Michael I Goran; Laurence N Kolonel; Brian E Henderson; Loïc Le Marchand Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-11 Impact factor: 4.254
Authors: Sadir J Alrawi; Robert E Carroll; Hank C Hill; John F Gibbs; Dongfeng Tan; Bruce M Brenner; Norma J Nowak; Helen Swede; Daniel L Stoler; Garth R Anderson Journal: Mutat Res Date: 2006-06-27 Impact factor: 2.433
Authors: Richard G Stevens; Helen Swede; Christopher D Heinen; Melissa Jablonski; Michael Grupka; Barry Ross; Melissa Parente; Jennifer S Tirnauer; Charles Giardina; Thiruchandurai V Rajan; Daniel W Rosenberg; Joel Levine Journal: Cancer Lett Date: 2006-09-06 Impact factor: 8.679
Authors: Daniel W Rosenberg; Shi Yang; Devon C Pleau; Emily J Greenspan; Richard G Stevens; Thiruchandurai V Rajan; Christopher D Heinen; Joel Levine; Yijian Zhou; Michael J O'Brien Journal: Cancer Res Date: 2007-04-15 Impact factor: 12.701
Authors: Joseph C Anderson; Catherine R Messina; Fouad Dakhllalah; Biju Abraham; Zvi Alpern; Carol Martin; Patricia M Hubbard; Roger Grimson; Robert D Shaw Journal: J Clin Gastroenterol Date: 2007-03 Impact factor: 3.062
Authors: I T Gram; T Norat; S Rinaldi; L Dossus; A Lukanova; B Téhard; F Clavel-Chapelon; C H van Gils; P A H van Noord; P H M Peeters; H B Bueno-de-Mesquita; G Nagel; J Linseisen; P H Lahmann; H Boeing; D Palli; C Sacerdote; S Panico; R Tumino; S Sieri; M Dorronsoro; J R Quirós; C A Navarro; A Barricarte; M-J Tormo; C A González; K Overvad; S Paaske Johnsen; A Olsen; A Tjønneland; R Travis; N Allen; S Bingham; K-T Khaw; P Stattin; A Trichopoulou; V Kalapothaki; T Psaltopoulou; C Casagrande; E Riboli; R Kaaks Journal: Int J Obes (Lond) Date: 2006-03-21 Impact factor: 5.095
Authors: Paul F Pinsky; James Fleshman; Matt Mutch; Christopher Rall; Aline Charabaty; David Seligson; Sarah Dry; Asad Umar; Robert E Schoen Journal: Cancer Prev Res (Phila) Date: 2010-06-22